Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : To Work On New Cancer Treatment With iTeos Therapeutics

06/14/2021 | 07:39am EDT


ę MT Newswires 2021
All news about GLAXOSMITHKLINE PLC
02:44aSanofi raises profit forecast after second quarter beat
RE
07/28GLAXOSMITHKLINE : GSK delivers strong Q2 sales of ú8.1 billion, +6% AER, +15% CE..
PU
07/28GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
07/28VIR BIOTECHNOLOGY : GlaxoSmithKline Secure Deal With EU for Supply of Experiment..
MT
07/28GLAXOSMITHKLINE : JP Morgan reaffirms its Neutral rating
MD
07/28GLAXOSMITHKLINE : Receives a Buy rating from Jefferies
MD
07/28GLAXOSMITHKLINE : Goldman Sachs reiterates its Buy rating
MD
07/28GLAXOSMITHKLINE : GSK H1 Net Profit, Turnover Slumps, Confirms 2021 Guidance
MT
07/28GLAXOSMITHKLINE : Posts Higher Q2 Adjusted Earnings, Sales
MT
07/28GLAXOSMITHKLINE : Q2 2021 US dollar translation PDF - 159.8KB
PU
More news
Financials
Sales 2021 32 702 M 45 566 M 45 566 M
Net income 2021 3 306 M 4 606 M 4 606 M
Net Debt 2021 21 750 M 30 305 M 30 305 M
P/E ratio 2021 21,2x
Yield 2021 5,71%
Capitalization 70 137 M 97 346 M 97 726 M
EV / Sales 2021 2,81x
EV / Sales 2022 2,59x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 1 401,60 GBX
Average target price 1 541,50 GBX
Spread / Average Target 9,98%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC4.44%97 346
JOHNSON & JOHNSON9.40%454 682
ROCHE HOLDING AG11.50%329 752
PFIZER, INC.18.04%235 663
NOVARTIS AG-0.44%221 987
ELI LILLY AND COMPANY46.00%221 420